|
Life Science Nation Newsletter | December 18, 2014 | Issue 93
|
|
 Life Science Investor Mandates (Dec. 10 - Dec. 17) |
| |
|
Seeking Healthcare IT and Tech Enabled Devices
|
Seeking Early Stage Life Science Opportunities throughout the US and Canada
|
|
Seeking mHealth, Gene Sequencing, Immunotherapy, Stem cells, and Antibody Therapeutics
|
|
Year-End Roundup: Investor Mandates
|
Year-End Roundup: Pharma Licensing Deals
|
RESI Double Angel Panel Announcement
|
|
|
|
 This year was by far LSN's best for new and updated investor mandates. With more still coming in, thus far in 2014 we have been able to add an additional 650 new unique interviews with life science investors to our database of over 5,000 global investors. These investors spanned 33 countries and all 10 investor categories. (See Figure 1.)
As a result of LSN Research's focus on early stage life science investors, the majority of the firms we spoke with in 2014 were making maximum allocations in a range of $5 million to $14.9 million. However, it is also worth noting that many investors were seeking to make larger and smaller allocations. When seeking funding, understanding the potential investment size investors are looking to make in a given round is a huge factor regarding fit. You don't want to waste your time chasing investors whose allocation size is way outside the range for your round... 
|
 |
|
|
By Lucy Parkinson, Senior Research Manager, LSN
In recent years, big pharmaceutical companies have filled their pipelines by turning to smaller partners to find innovative products, and 2014 has been no exception. This year has produced so much dealmaking news that you may have lost track of all the new partnerships. But we've dug into the LSN Licensing Deals Platform to examine the key data points from the year's pharmaceutical licensing activity.
Preclinical and Phase II Deals Dominated
Although about a quarter of the licensing deals LSN tracked involved a drug discovery platform, the rest were focused on one or more clinical assets. Of these deals, most were inked either during preclinical development or in Phase II. (See Figure 1.) It's common wisdom that most assets find a partner in Phase II, but this data demonstrates that it's important to think about a strategic partner even before entering the clinic...
|
|
|
By Tom Crosby, RESI Conference Manager, LSN
Angels represent an extremely important pool of capital for a fundraising entrepreneur, especially now that they have begun syndicating and participating in larger financing rounds. To help RESI attendees better understand how to receive an allocation from an angel, LSN has assembled two top panels of accredited investors - one session focused on biotech investments and the other on medical device opportunities.
The Biotech Angel Groups sessions will be moderated by Bill Whitaker, Managing Director, Co-Chair Life Science Section, Golden Seeds, and will hear from:
- Brian Frenzel, Member, Band of Angels
- Karl Handelsman, Member, Board of Directors, Life Science Angels
- Bernie Rudnick, Managing Director, Mid Atlantic Bio Angels
- Barbara Nelsen, Member, Sofia Angels
The Medtech Angel Groups sessions will be moderated by Allan May, Managing Director, Life Science Angels, and will hear from:
- Karen Drexler, Founder, Astia
- Randy Barko, Member, Hub Investment Management Group
- Steven Pollitt, Board Member, Sand Hill Angels
- Richard Koffler, Board of Directors, Tech Coast Angels...
|
|
 |
|
|
|
|
|
Editors:
Nono Hu, Senior Manager, Branding & Messaging, LSN
|
|
|
|
